vs
Apellis Pharmaceuticals, Inc.（APLS）与STAG Industrial, Inc.（STAG）财务数据对比。点击上方公司名可切换其他公司
STAG Industrial, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.1倍（$224.2M vs $199.9M），STAG Industrial, Inc.净利率更高（27.6% vs -29.5%，领先57.1%），STAG Industrial, Inc.同比增速更快（9.1% vs -5.9%），过去两年STAG Industrial, Inc.的营收复合增速更高（8.7% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Stag Arms是2003年5月成立的枪械制造商，总部位于美国怀俄明州夏延，主打Stag-15系列AR-15步枪，所有枪械及配件均为美国本土生产，最知名的是适配左撇子操作习惯的定制款AR-15步枪。
APLS vs STAG — 直观对比
营收规模更大
STAG
是对方的1.1倍
$199.9M
营收增速更快
STAG
高出15.0%
-5.9%
净利率更高
STAG
高出57.1%
-29.5%
两年增速更快
STAG
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $224.2M |
| 净利润 | $-59.0M | $62.0M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | 27.6% |
| 营收同比 | -5.9% | 9.1% |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSSTAG
| Q1 26 | — | $224.2M | ||
| Q4 25 | $199.9M | $220.9M | ||
| Q3 25 | $458.6M | $211.1M | ||
| Q2 25 | $178.5M | $207.6M | ||
| Q1 25 | $166.8M | $205.6M | ||
| Q4 24 | $212.5M | $199.3M | ||
| Q3 24 | $196.8M | $190.7M | ||
| Q2 24 | $199.7M | $189.8M |
净利润APLSSTAG
| Q1 26 | — | $62.0M | ||
| Q4 25 | $-59.0M | $83.5M | ||
| Q3 25 | $215.7M | $48.6M | ||
| Q2 25 | $-42.2M | $50.0M | ||
| Q1 25 | $-92.2M | $91.4M | ||
| Q4 24 | $-36.4M | $51.0M | ||
| Q3 24 | $-57.4M | $41.9M | ||
| Q2 24 | $-37.7M | $59.8M |
营业利润率APLSSTAG
| Q1 26 | — | — | ||
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | — | ||
| Q2 25 | -18.6% | — | ||
| Q1 25 | -50.0% | — | ||
| Q4 24 | -12.3% | — | ||
| Q3 24 | -24.0% | — | ||
| Q2 24 | -14.7% | — |
净利率APLSSTAG
| Q1 26 | — | 27.6% | ||
| Q4 25 | -29.5% | 37.8% | ||
| Q3 25 | 47.0% | 23.0% | ||
| Q2 25 | -23.6% | 24.1% | ||
| Q1 25 | -55.3% | 44.5% | ||
| Q4 24 | -17.1% | 25.6% | ||
| Q3 24 | -29.2% | 21.9% | ||
| Q2 24 | -18.9% | 31.5% |
每股收益（稀释后）APLSSTAG
| Q1 26 | — | $0.32 | ||
| Q4 25 | $-0.40 | — | ||
| Q3 25 | $1.67 | — | ||
| Q2 25 | $-0.33 | — | ||
| Q1 25 | $-0.74 | — | ||
| Q4 24 | $-0.30 | — | ||
| Q3 24 | $-0.46 | — | ||
| Q2 24 | $-0.30 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $8.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $3.6B |
| 总资产 | $1.1B | $7.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSSTAG
| Q1 26 | — | $8.9M | ||
| Q4 25 | $466.2M | $14.9M | ||
| Q3 25 | $479.2M | $17.3M | ||
| Q2 25 | $370.0M | $15.4M | ||
| Q1 25 | $358.4M | $9.3M | ||
| Q4 24 | $411.3M | $36.3M | ||
| Q3 24 | $396.9M | $70.0M | ||
| Q2 24 | $360.1M | $33.3M |
总债务APLSSTAG
| Q1 26 | — | — | ||
| Q4 25 | — | $3.3B | ||
| Q3 25 | — | $3.1B | ||
| Q2 25 | — | $3.0B | ||
| Q1 25 | — | $3.0B | ||
| Q4 24 | — | $3.0B | ||
| Q3 24 | — | $2.9B | ||
| Q2 24 | — | $2.8B |
股东权益APLSSTAG
| Q1 26 | — | $3.6B | ||
| Q4 25 | $370.1M | $3.6B | ||
| Q3 25 | $401.2M | $3.4B | ||
| Q2 25 | $156.3M | $3.4B | ||
| Q1 25 | $164.2M | $3.5B | ||
| Q4 24 | $228.5M | $3.5B | ||
| Q3 24 | $237.1M | $3.3B | ||
| Q2 24 | $264.3M | $3.3B |
总资产APLSSTAG
| Q1 26 | — | $7.2B | ||
| Q4 25 | $1.1B | $7.2B | ||
| Q3 25 | $1.1B | $6.9B | ||
| Q2 25 | $821.4M | $6.8B | ||
| Q1 25 | $807.3M | $6.8B | ||
| Q4 24 | $885.1M | $6.8B | ||
| Q3 24 | $901.9M | $6.6B | ||
| Q2 24 | $904.5M | $6.4B |
负债/权益比APLSSTAG
| Q1 26 | — | — | ||
| Q4 25 | — | 0.91× | ||
| Q3 25 | — | 0.91× | ||
| Q2 25 | — | 0.88× | ||
| Q1 25 | — | 0.87× | ||
| Q4 24 | — | 0.88× | ||
| Q3 24 | — | 0.89× | ||
| Q2 24 | — | 0.84× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | 3.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSSTAG
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $104.5M | ||
| Q3 25 | $108.5M | $143.5M | ||
| Q2 25 | $4.4M | $111.9M | ||
| Q1 25 | $-53.4M | $103.5M | ||
| Q4 24 | $19.4M | $104.9M | ||
| Q3 24 | $34.1M | $128.0M | ||
| Q2 24 | $-8.3M | $122.2M |
自由现金流APLSSTAG
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $43.8M | ||
| Q3 25 | $108.3M | $95.5M | ||
| Q2 25 | $4.4M | $62.3M | ||
| Q1 25 | $-53.4M | $57.2M | ||
| Q4 24 | $19.3M | $37.6M | ||
| Q3 24 | — | $86.7M | ||
| Q2 24 | $-8.4M | $105.0M |
自由现金流率APLSSTAG
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 19.8% | ||
| Q3 25 | 23.6% | 45.2% | ||
| Q2 25 | 2.5% | 30.0% | ||
| Q1 25 | -32.0% | 27.8% | ||
| Q4 24 | 9.1% | 18.8% | ||
| Q3 24 | — | 45.5% | ||
| Q2 24 | -4.2% | 55.3% |
资本支出强度APLSSTAG
| Q1 26 | — | 3.9% | ||
| Q4 25 | 0.1% | 27.4% | ||
| Q3 25 | 0.0% | 22.7% | ||
| Q2 25 | 0.0% | 23.9% | ||
| Q1 25 | 0.0% | 22.5% | ||
| Q4 24 | 0.0% | 33.8% | ||
| Q3 24 | 0.0% | 21.6% | ||
| Q2 24 | 0.0% | 9.1% |
现金转化率APLSSTAG
| Q1 26 | — | — | ||
| Q4 25 | — | 1.25× | ||
| Q3 25 | 0.50× | 2.95× | ||
| Q2 25 | — | 2.24× | ||
| Q1 25 | — | 1.13× | ||
| Q4 24 | — | 2.06× | ||
| Q3 24 | — | 3.06× | ||
| Q2 24 | — | 2.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
STAG
暂无分部数据
